Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Crypto News: Pepeto Rolls Out Its DeFi Tools While Bitcoin Price Prediction Targets $200,000 and Whale Wallets Reveal Their Next Target

August 17, 2026

Blaze Pizza Fires Up New Restaurant in Cincinnati's Oakley Neighborhood with Free Pizza Day Celebration

August 17, 2026

Quebec, Newfoundland and Labrador announce Churchill Falls energy deal

August 17, 2026

CORRECTION: TDECU Board Elects Lavonne Burke as New Chair

August 17, 2026

Sonos finally added Live Activities controls for your iPhone lockscreen

August 17, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
Press Release

Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.

By News RoomJune 9, 20262 Mins Read
Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
Share
Facebook Twitter LinkedIn Pinterest Email

BEDMINSTER, N.J., June 09, 2026 (GLOBE NEWSWIRE) — Alembic Therapeutics, LLC announces the acquisition of NUVESSA® (metronidazole vaginal gel 1.3%), an FDA-approved prescription medication indicated for the treatment of bacterial vaginal infections in females 12 years of age and older, from Exeltis USA, Inc. This acquisition represents an important milestone in Alembic Therapeutics’ ongoing commitment to expanding its women’s health portfolio and increasing patient access to proven treatment options. Through this transaction, Alembic Therapeutics assumes responsibility for the commercialization and distribution of NUVESSA in the United States.

NUVESSA is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. NUVESSA is designed as a convenient single-dose, pre-filled disposable applicator, which delivers approximately 5g of gel containing 65mg of metronidazole, administered once a day at bedtime intravaginally. NUVESSA is contraindicated in persons who have shown hypersensitivity to metronidazole, parabens, any component of the formulation, or other nitroimidazole derivatives.

NUVESSA will continue to be available nationwide through retail and specialty pharmacy distribution channels. Healthcare providers can continue prescribing NUVESSA in accordance with the approved prescribing information for appropriate patients. The full prescribing information should be consulted for complete details regarding approved indications, dosing, administration, contraindications, warnings, and safety information.

Alembic Therapeutics is dedicated to delivering high-quality pharmaceutical products and innovative healthcare solutions that improve patient outcomes and expand access to care across multiple therapeutic categories.

Alembic Therapeutics, LLC
550 Hills Drive, Suite 110
Bedminster NJ 07921
908-569-7456 • [email protected]
www.alembictherapeutics.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c2b9304-e79b-43e8-8e2c-9cb1ad8774ae

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Crypto News: Pepeto Rolls Out Its DeFi Tools While Bitcoin Price Prediction Targets $200,000 and Whale Wallets Reveal Their Next Target

Blaze Pizza Fires Up New Restaurant in Cincinnati's Oakley Neighborhood with Free Pizza Day Celebration

CORRECTION: TDECU Board Elects Lavonne Burke as New Chair

Rally House and Big Ten Conference Launch Exclusive Football Championship Giveaway

Crypto News: Moonberg Sells Out Presale Stage 1 As XRP Price Prediction Targets $5

North America Circular Polymers Market Set to Expand at 7.8% CAGR From 2026 to 2035

Fiberglass Doors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

Offshore Wind Market by Component, Water Depth, Foundation Type, Turbine Rating, and Region – Global Forecast to 2035

Following Billion-Dollar Funding Surges for Custom Inference Silicon and Liquid-Cooled Servers, New Study Maps AI Hardware Ecosystem Out to 2040

Editors Picks

Blaze Pizza Fires Up New Restaurant in Cincinnati's Oakley Neighborhood with Free Pizza Day Celebration

August 17, 2026

Quebec, Newfoundland and Labrador announce Churchill Falls energy deal

August 17, 2026

CORRECTION: TDECU Board Elects Lavonne Burke as New Chair

August 17, 2026

Sonos finally added Live Activities controls for your iPhone lockscreen

August 17, 2026

Latest News

Rally House and Big Ten Conference Launch Exclusive Football Championship Giveaway

August 17, 2026

Crypto News: Moonberg Sells Out Presale Stage 1 As XRP Price Prediction Targets $5

August 17, 2026

North America Circular Polymers Market Set to Expand at 7.8% CAGR From 2026 to 2035

August 17, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version